• CureVac Appoints Chief Development Officer contractpharma
    June 03, 2021
    ​CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Klaus Edvardsen, MD, PhD, as chief development officer.
PharmaSources Customer Service